SOURCE: Vicor Technologies, Inc.

September 16, 2008 09:00 ET

Vicor Technologies Announces Publication of Positive Results Obtained in Study Conducted in Collaboration With the U.S. Army

BOCA RATON, FL--(Marketwire - September 16, 2008) - Vicor Technologies, Inc. (OTCBB: VCRT) today announced publication of the results of its first clinical study conducted in collaboration with the U.S. Army Institute of Surgical Research (USAISR). Vicor Technologies is a biotechnology company that has developed the PD2i, a patented, proprietary algorithm that is now in trials for FDA 510(k) approval for a) measuring heart rate variability (PD2i Analyzer), b) risk stratifying combat and civilian trauma victims (PD2i VS), and c) identifying patients at risk of suffering sudden cardiac death (PD2i CA).

The study is an analysis of data obtained from electrocardiograms of 11 combat casualty victims using nonlinear methods including Vicor's PD2i Analyzer All of the wounded soldiers demonstrated abnormal heart rate variability (HRV). Those requiring immediate life saving intervention all had minimum PD2i values less than one. Entitled "Exploration of Heart-rate complexity to determine the need for lifesaving interventions in combat casualties," the study appears in the Journal of Critical Care (Volume 23, Issue 2, Pages 265-266).

"This study clearly demonstrates the unique ability of Vicor's PD2i Analyzer to accurately measure heart rate variability and the utility of HRV measure in diagnosing the need for immediate life saving intervention," stated Mr. David Fater, Vicor Technologies' President and CEO. "We expect that future studies of the PD2i Analyzer's effectiveness will prove equally positive and further our efforts to commercialize the PD2i Analyzer, for measuring heart rate variability, generally, and the PD2i VS, for risk stratifying combat and civilian trauma victims, specifically," Mr. Fater concluded.

Vicor Technologies and the U.S. Army Institute of Surgical Research (USAISR) entered into a Collaborative Research and Development Agreement (CRADA) for the "Prediction of Injury Severity and Outcome in the Critically Ill Using the Point Correlation Dimension Algorithm, or PD2i" in January 2008. Under the CRADA, the USAISR and Vicor are testing the efficacy of the PD2i Analyzer as a vital sign application on four distinct cohorts: animal trauma, human trauma, combat casualties, and burn victims.

About Vicor Technologies, Inc.

Vicor Technologies, Inc. (OTCBB: VCRT) is a development-stage biotechnology company focused on the development of innovative diagnostics. Vicor's PD2i Analyzer, PD2i Vital Sign (PD2i VS), and PD2i Cardiac Analyzer (PD2i CA) employ the firm's patented, proprietary point correlation dimension algorithm (PD2i), a deterministic, non-linear analytic measure that accurately evaluates electrophysiological potentials with high sensitivity and high specificity to predict future pathological events.

The PD2i Analyzer measures heart rate variability (HRV) through the analysis of electrocardiographic data. The clinical significance of HRV and use of the PD2i Analyzer as a diagnostic tool is physician-determined. Vicor Technologies expects to receive FDA approval for the PD2i Analyzer in 4Q08. Such approval will enable Vicor Technologies to market and distribute the PD2i Analyzer for use while completing clinical trials and the FDA approval process for its PD2i VS and PD2i CA.

The PD2i VS enables risk stratification of trauma severity to identify those in need of immediate life saving intervention and improve emergency triage efforts. The PD2i VS is currently in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research.

The PD2i CA identifies patients at risk of suffering a fatal arrhythmic event or sudden cardiac death within six months. The PD2i CA is currently involved in a multi-site, multi-year trial (the VITAL Trial) being conducted by the Harvard Clinical Research Institute.

Vicor Technologies anticipates developing additional applications using the PD2i algorithm to enable early detection of Alzheimer's Disease, and a variety of other disorders and diseases.

More information about Vicor Technologies may be found at

The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein

Caution Regarding Forward-Looking Statements

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: the results of clinical studies analyzing the effectiveness of the PD2i Analyzer, our ability to obtain FDA approval of the PD2i Cardiac Analyzer for military and civilian applications, our ability to continue to receive financing sufficient to complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 8-14

Contact Information